Clinical Trials Sponsored by Karos Pharmaceuticals

Total 19622 results

Karos Pharmaceuticals

Completed

Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585

Pulmonary Arterial Hypertension

United States
Kalos Medical

Recruiting

DENEX Renal Denervation in Patients With Hypertension on no Antihypertensive Medications

Cardiovascular Diseases | Vascular Diseases | Hypertension

Greece
Kalos Medical

Completed

DENEX Renal Denervation in Patients With Uncontrolled Hypertension: Safety Study

Uncontrolled Hypertension

Korea, Republic of
Kartos Therapeutics, Inc.

Withdrawn

Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer
Akros Pharma Inc.

Withdrawn

Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial Hypertension (RELIEF-PAH)

Pulmonary Arterial Hypertension
Karus Therapeutics Limited

Completed

The Safety, Pharmacokinetic and Pharmacodynamic Effect of KA2237 (PI3 Kinase p110β/δ Inhibitor) In B Cell Lymphoma

Lymphoma, B Cell

United States
Akros Pharma Inc.

Completed

Mass Balance Study of JTZ-951 in Subjects With End-stage Renal Disease on Hemodialysis

Anemia of Chronic Kidney Disease

United States
Akros Pharma Inc.

Completed

Study to Evaluate Effect of Lapatinib on Pharmacokinetics of JTZ-951 in Subjects With End-stage Renal Disease

Anemia of Chronic Kidney Disease

United States
Akros Pharma Inc.

Completed

Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease

Anemia in Chronic Kidney Disease

United States
Akros Pharma Inc.

Terminated

Efficacy and Safety Study of JTT-654 in Type 2 Diabetic Patients

Type II Diabetes Mellitus

United States
Kalos Medical

Recruiting

DENEX, Renal Denervation Therapy, in Patients With Hypertension on no or 1-3 Antihypertensive Medications

Cardiovascular Diseases | Vascular Diseases | Hypertension

Korea, Republic of
Kuros Biosurgery AG
Avania; Kuros BioSciences B.V.

Active, not recruiting

KUR-113 Bone Graft Versus Local Autograft for the Treatment of Single-level Transforaminal Lumbar Interbody Fusion (STRUCTURE)

Degenerative Disc Disease | Spinal Fusion

United States
Kars State Hospital

Completed

Online Information on Myofascial Pain Syndrome

Myofascial Pain Syndrome, Diffuse

Turkey
Kars State Hospital

Unknown

Dry Needling With And Without Kinesio Taping® in The Non-Specific Chronic Low Back Pain

Non-Spesific Chronic Low Back Pain
Karo Bio AB

Completed

LDL-Cholesterol Lowering Effect of KB2115 as Add on to Statin

Dyslipidemia

Sweden
Karo Bio AB

Completed

LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe

Hypercholesterolemia

Sweden
Karo Bio AB

Completed

Eprotirome for the Treatment of Dyslipidemia, Efficacy and Safety 12-Week, Phase ii Study to Assess the Safety and Efficacy of KB2115 in Patients With Primary Hypercholesterolemia

Primary Hypercholesterolemia

Sweden
Keros Therapeutics, Inc.

Recruiting

A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study).

Pulmonary Arterial Hypertension

United States, Australia
Keros Therapeutics, Inc.

Recruiting

A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Cytopenia

Australia, Spain, United States, Israel, France, Germany, New Zealand, Czechia
Kartos Therapeutics, Inc.

Recruiting

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera MF (Post-PV-MF) | Post-Essential Thrombocythemia MF (Post-ET-MF)

United States, Korea, Republic of, Germany, Australia, Hungary, France, Spain, Italy, Taiwan, Thailand, Brazil, Poland, Turkey, Israel, Portugal, Romania, Argentina, Bulgaria, Canada, Croatia, Czechia, Lithuania, Mexico, Philippines, United... and more
Kartos Therapeutics, Inc.

Terminated

KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer

Small Cell Lung Carcinoma | Small-cell Lung Cancer | Small Cell Lung Cancer Extensive Stage | Small Cell Lung Cancer Recurrent

Germany, Spain, France, Australia, United States, Korea, Republic of, Hungary
Akros Pharma Inc.

Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States
Kuros Biosurgery AG

Completed

Performance and Safety of I-020805 in Prevention of Cerebrospinal Fluid (CSF) Leakage Following Elective Craniotomy

Cerebrospinal Fluid Leakage

Germany, Hungary
Akros Pharma Inc.

Completed

Study of Safety, Tolerability and Pharmacokinetics of Single Oral JTT-251 Doses in Healthy and Type 2 Diabetic Subjects

Diabetes Mellitus

United States
Akros Pharma Inc.

Completed

Efficacy and Safety Study of JTT-302 in Subjects With Low HDL-C Levels

Dyslipidemia

United States
Akros Pharma Inc.

Completed

Safety and Efficacy Study of JTT-130 in Obese Type 2 Diabetic Patients

Type II Diabetes Mellitus

United States, Russian Federation, Czech Republic, Hungary, Netherlands
Kuros Biosurgery AG

Completed

A Dose Finding Study of Topically Applied I-020201 as an Adjunct to Good Standard-of-care in Patients With Chronic Diabetic Foot Ulcers (DFU)

Diabetic Foot Ulcer

Czech Republic, Germany, Hungary, Romania, Russian Federation, Serbia
Akros Pharma Inc.

Completed

Safety, Tolerability and Pharmacokinetics Study Assessing Ascending Single Oral JTK-853 Doses in Healthy Subjects

Healthy

United States
Akros Pharma Inc.

Terminated

Two Week Study Evaluating Safety, Tolerability and Pharmacokinetics of Multiple Doses of JTK-853 in Healthy Subjects

Healthy

United States
Akros Pharma Inc.

Completed

Safety and Efficacy Study of JTT-705 in Combination With Simvastatin 40 mg in Patients With Low High-Density Lipoprotein (HDL) Levels

Dyslipidemia

Netherlands
Akros Pharma Inc.

Completed

Efficacy and Safety Study of JTT-705 in Combination With Pravastatin 40 mg in Patients With Type II Hyperlipidemia

Type II Hyperlipidemia

Netherlands
Akros Pharma Inc.

Completed

Safety and Efficacy Study of JTT-705 in Combination With Atorvastatin 20 mg in Patients With Low High-Density Lipoprotein (HDL) Levels

Dyslipidemia

Netherlands
Kartos Therapeutics, Inc.
GlaxoSmithKline

Completed

A Phase 1b/2a Study Evaluating AMG 232 in Metastatic Melanoma

Melanoma | Cancer | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology Patients

United States, Australia
Keros Therapeutics, Inc.

Recruiting

A Study to Evaluate the Safety and Preliminary Efficacy of a Response-guided Dose Titration of KER-047 in the Treatment of Functional IDA (Iron Deficiency Anemia).

Iron Deficiency Anemia

Australia, Israel, Romania
Kartos Therapeutics, Inc.

Recruiting

Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera Myelofibrosis (Post-PV-MF) | Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)

United States, Mexico, Bulgaria, Poland, Russian Federation, Belarus, Georgia, South Africa, Ukraine
Kartos Therapeutics, Inc.

Recruiting

KRT-232 and TKI Study in Chronic Myeloid Leukemia

Chronic Myeloid Leukemia

Italy, Spain, United States, Korea, Republic of, France, Poland, Canada, Russian Federation
Kartos Therapeutics, Inc.

Recruiting

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

Belgium, Korea, Republic of, United States, United Kingdom, Italy, Switzerland, Australia, France, Poland, Portugal, Czechia
Kartos Therapeutics, Inc.

Recruiting

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Myelofibrosis

United States, France, Australia, Spain, Germany, Bulgaria, Israel, Italy, Poland
Kartos Therapeutics, Inc.

Recruiting

Navtemadlin (KRT-232) With or Without Anti-PD-1/Anti-PD-L1 for the Treatment of Patients With Merkel Cell Carcinoma

Merkel Cell Carcinoma

United States, Netherlands, Korea, Republic of, France, Germany, Spain, Canada, Italy, Australia, Brazil
Kartos Therapeutics, Inc.

Terminated

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)

Relapsed or Refractory Acute Myeloid Leukemia (AML) | Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)

United States, Spain, Korea, Republic of, Belgium, United Kingdom, Hungary, France, Germany, Israel, Australia, Italy, Poland
Kartos Therapeutics, Inc.

Completed

A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma

Cancer | Glioblastoma | Multiple Myeloma | Advanced Solid Tumors | Oncology | Tumors | Advanced Malignancy | Oncology Patients

United States, France, Netherlands
Akros Pharma Inc.

Completed

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis (IMPACT-PS)

Skin Diseases | Psoriasis | Plaque Psoriasis

United States, Canada, Poland
Akros Pharma Inc.

Terminated

Study to Evaluate the Safety and Efficacy of JTE-051 in Subjects With Moderate to Severe Plaque Psoriasis (CLEAR-PS)

Skin Diseases | Plaque Psoriasis

United States, Canada
Akros Pharma Inc.

Completed

Study to Evaluate Efficacy, Safety and Tolerability of JTE-051 in Subjects With Active Rheumatoid Arthritis (MOVE-RA)

Rheumatoid Arthritis

Ukraine, United States, Argentina, Bulgaria, Romania, Peru, Russian Federation, Mexico, Colombia, Poland
Karus Therapeutics Limited

Completed

Safety,Tolerability and MTD KA2507 (HDAC6 Inhibitor) in Patients With Solid Tumours (HDAC6i)

Solid Tumor, Adult

United States
Kartos Therapeutics, Inc.

Unknown

KRT-232 Compared to Ruxolitinib in Patients With Phlebotomy-Dependent Polycythemia Vera

Polycythemia Vera

United States, Poland, Spain, Germany, Hungary, France
Kartos Therapeutics, Inc.

Completed

A Phase 1b Study Evaluating AMG 232 Alone and in Combination With Trametinib in Acute Myeloid Leukemia

Acute Myeloid Leukemia | Cancer | Oncology | Advanced Malignancy | Oncology Patients

United States
Akros Pharma Inc.

Completed

Study to Evaluate Safety,Tolerability,Pharmacodynamics & Pharmacokinetics of JTE-451 in Active Plaque Psoriasis Subjects

Skin Diseases | Psoriasis | Plaque Psoriasis

Canada
Akros Pharma Inc.

Terminated

Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of JTT-252

Diabetes Mellitus

United States
Akros Pharma Inc.

Completed

Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease

Anemia of Chronic Kidney Disease

United States

Clinical Trials Sponsored by Karos Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations